NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-029-2019-0-KR-09 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION KR National Stage 2021-7026169 Pending
NCI E-065-2016-0-US-05 COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPY US DIV 17/402,751 Abandoned
NINDS E-001-2019-1-US-02 Handgrip Relaxometer Devices US National Stage 17/430,891 Pending
NCI E-029-2019-0-EP-07 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION EP National Stage 20705599.7 Pending
NEI E-195-2020-0-PCT-03 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method PCT PCT PCT/US2021/045675 Expired
NINDS E-102-2019-1-CA-03 HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC RESONANCE IMAGING OF CORTICAL LESIONS CA National Stage 3130216 Pending
NIA E-013-2010-0-BR-17 THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS BR DIV BR122021015782-0 Issued
NIAID E-105-2020-0-PCT-02 Replication-Competent Adenovirus Type 4-HIV Env Vaccines And Their Use PCT PCT PCT/US2021/045389 Expired
NCI E-107-2020-0-PCT-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS PCT PCT PCT/US2021/045305 Expired
NCI E-050-2014-0-EP-20 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon EP DIV 21190529.4 Pending
NIAID E-099-2016-0-AU-21 USE OF GRAM NEGATIVE SPECIES TO TREAT ATOPIC DERMATITIS AU DIV 2021215132 Abandoned
NCATS E-200-2020-0-PCT-02 REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY PCT PCT PCT/US2021/045184 Expired
NIAID E-147-2015-0-HK-16 BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST HIV-1 V1V2 ENV REGION HK EP 42021036522.7 Pending
NCI E-053-2019-0-EP-11 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES EP National Stage 20711371.3 Pending
NCI E-053-2019-0-US-12 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES US National Stage 17/429,391 Pending
NCI E-190-2014-0-US-42 VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS US CON 17/395,369 11806406 Issued PDF
NCI E-053-2019-0-AU-08 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES AU National Stage 2020219097 Pending
NEI E-212-2015-0-JP-09 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS JP DIV 2021-128087 Pending
NCI E-148-2011-0-IL-51 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer IL DIV 285335 Issued
CC E-183-2016-0-EP-11 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP DIV 21189335.9 Pending
NCI E-247-2015-0-US-08 IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA US CON 17/392,075 Pending
NCATS E-232-2020-0-PCT-02 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF PCT PCT PCT/US2021/044089 Expired
NCATS E-027-2021-0-PC-01 QUANTUM DOT CONJUGATED VIRUS SPIKE PROTEIN FOR CELL-BASED BIO-SENSING SYSTEMS AND DRUG SCREENING PCT PCT PCT/US2021/043846 Expired
NCI E-196-2018-0-PCT-02 INSERT FOR PREPARING CELL CULTURE CHAMBERS PCT PCT PCT/US2021/43930 Expired
NCATS E-027-2021-0-US-02 Quantum Dot Conjugated Virus Spike Protein For Cell-based Bio-sensing Systems And Drug Screening US ORD 17/389,645 Pending
NCI E-141-2008-0-US-35 Complexes Of IL-15 And IL-15R AIpha And Uses Thereof US CON 17/390,495 Pending
NCI E-230-2012-0-JP-64 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 JP DIV 2021-124003 Issued
NCI E-107-2021-0-AU-01 Use Of TomentosenalA For Treatment Of Skin Conditions AU ORD 2021902329 Issued
NCATS E-004-2016-0-AU-01 SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF AU DIV 2021209257 Pending
NIAID E-052-2017-4-MY-56 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection MY DIV PI 2021004277 Pending
NHLBI E-045-2018-0-US-07 Vascular Anchoring Introducer Sheath US DIV 17/385,230 Pending
NINDS E-201-2020-0-PCT-02 NANOBODIES DIRECTED TO CORONAVIRUS SPIKE PROTEIN RECEPTOR BINDING DOMAIN AND USES THEREOF PCT PCT PCT/US21/42883 Expired
NINDS E-201-2020-0-EP-03 NANOBODIES DIRECTED TO CORONAVIRUS SPIKE PROTEIN RECEPTOR BINDING DOMAIN AND USES THEREOF EP National Stage 21755255.3 Pending
CC E-103-2018-0-US-03 METHODS AND COMPOSITIONS FOR DETECTING TRANSFUSION-TRANSMITTED PATHOGENS US National Stage 17/425,228 Pending
NCI E-050-2014-0-CN-21 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon CN DIV 202110829496.3 Abandoned
NIAID E-052-2017-0-TW-12 Trispecific Binding Protein TW DIV 110126977 Pending
NCI E-029-2019-0-CN-06 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION CN National Stage 202080010373.0 Pending
NIAID E-089-2019-0-US-03 SIRPalpha Expression On T Cells Is A Biomarker For Functional T Cells During Exhaustion US National Stage 17/425,224 Pending
NCI E-029-2019-0-AU-04 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION AU National Stage 2020211922 Pending
NCI E-029-2019-0-US-10 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION US National Stage 17/424,591 Pending
NHLBI E-191-2020-0-PCT-02 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT PCT PCT PCT/US2021/042380 Expired
NCI E-029-2019-0-JP-08 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION JP National Stage 2021-542206 Pending
NHLBI E-191-2020-0-IL-05 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT IL National Stage 299776 Pending
NIAID E-215-2016-1-US-04 PREFUSION PIV F IMMUNOGENS AND THEIR USE US DIV 17/378,587 11845778 Issued PDF
NIAID E-032-2019-0-US-07 Nanoparticle-Based Influenza Virus Vaccines and Uses Thereof US National Stage 17/423,565 Pending
NCI E-029-2019-0-CA-05 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION CA National Stage 3127096 Pending
NCI E-055-2017-0-US-07 Combination Therapy of Immunotoxin and Checkpoint Inhibitor US CON 17/376,319 Abandoned
NIA E-249-2016-0-KR-18 METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM AND METHODS OF TREATING A CENTRAL NERVOUS SYSTEM DISEASE KR DIV 10-2021-7022385 Pending
NCI E-172-2020-0-PCT-02 HLA Class-II Restricted DRB1*01:01 T-cell Receptors Against The RASG12V Mutation PCT PCT PCT/US2021/041737 Expired
NCI E-195-2018-0-US-03 DETECTION OF BCL-2 FAMILY HETERODIMER COMPLEXES AND USE THEREOF US National Stage 17/422,972 Pending